Keywords
Vaccination coverage
Dengue
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To identify the efficacy of the Butantan-DV vaccine among Brazilians for four dengue serotypes, identify possible gaps in vaccine development, and clarify factors that influence efficacy. Methods: This is a scoping review, conducted between May and November 2024 with searches in PubMed/Medline, Virtual Health Library, ScienceDirect, Embase, Cochrane Library, and Scopus. Works with a time frame from 2019 to 2024 were included; texts in English and Portuguese; Full texts. Duplicate articles, monographs, course completion papers, review studies, and those that did not fit the objectives proposed by the researchers were excluded. Results: The sample consisted of 5 literatures, published between 2020 and 2024. From the bibliography, the efficacy, safety and immunogenicity of the Butantan-DV vaccine against dengue was verified. However, the vaccine does not present satisfactory efficacy data for the DENV-3 and DENV-4 serotypes. Final considerations: The Butantan-DV vaccine has the potential to mitigate cases of symptomatic dengue.
References
BARCELLOS C, et al. Climate change, thermal anomalies, and the recent progression of dengue in Brazil. Sci Rep, 2024; 14(1): 5948.
BORGES HCBG, et al. Avaliação dos testes rápidos para diagnóstico da dengue no Brasil. Vigilância Sanitária Em Debate, 2021; 9(1): 1-1.
BRASIL. Informe Semanal Edição Número 15 - Centro de Operações Emergenciais (COE) do Ministério da Saúde. 2024. Disponível em: https ://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/a/arbov iroses/informe-semanal/informe-semanal-no-15.pdf/view. Acessado em: 20 de maio de 2024.
BRASIL. MINISTÉRIO DA SAÚDE. Centro de Operação de Emergência (COE). Informe semanal edição N°21. [Brasília]: COE, 2 jul. 2024. Disponível em: https ://www.gov.br/saude/pt-br/assuntos/saude-de-a-a- z/a/aedes-aegypti/monitoramento-das-arboviroses. Acessado em: 02 de julho de 2024.
BRASIL. MINISTÉRIO DA SAÚDE. Guia de Vigilância em Saúde. Brasília, DF: Ministério da Saúde, 2022; 5.
DE SOUSA SC, et al. Factors associated with the occurrence of dengue epidemics in Brazil: a systematic review. Revista Panamericana de Salud Pública, 2021; 45(1): 84.
Dengue emergency in the Americas: time for a new continental eradication plan. The Lancet Regional Health – Americas, 2023; 22: 100539.
GURGEL-GONÇALVES R, et al. The greatest Dengue epidemic in Brazil: Surveillance, Prevention, and Control. Revista da Sociedade Brasileira de Medicina Tropical, 2024; 57: 203-2024.
KALLÁS EG, et al. Live, Attenuated, Tetravalent Butantan–Dengue Vaccine in Children and Adults. The new england journal of medicine, 2024; 390(5): 397–408.
KALLAS EG, et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan- DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. The Lancet Infectious Diseases, 2020; 20(7): 839–850.
MALIK S, et al. Tracing down the Updates on Dengue Virus—Molecular Biology, Antivirals, and Vaccine Strategies. Vaccines, 2023; 11 (8): 1328.
NOGUEIRA ML, et al. Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil. The Lancet Infectious Diseases, 2024; 1473309924003761.
OPAS. Alerta Epidemiológico: Dengue na Região das Américas - Organização Pan-Americana da Saúde/ Organização Mundial da Saúde. 2024. Disponível em: https ://www.paho.org/pt/documentos/alerta- epidemiologico-aumento-casos-dengue-na-regiao-das-americas-16-fevereiro-2024.
PAGE MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021; 71.
PELLETIER AN, et al. A pre-vaccination immune metabolic interplay determines the protective antibody response to a dengue virus vaccine. Cell Reports, 2024; 43 (7): 114370.
PETERS MD, et al. Scoping reviews. JBI Manual for Evidence Synthesis, 2024.
PRETO C, et al. Vaccination coverage and adherence to a dengue vaccination program in the state of Paraná, Brazil. Vaccine, 2021; 39 (4): 711–719.
RIVERA L, et al. Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003). Clinical Infectious Diseases, 2022; 75(1): 107–117.
ROY SK e BHATTACHARJEE S. Dengue virus: epidemiology, biology, and disease aetiology. Candian Journal of Microbiology, 2021; 67(10): 687–702.
SILVEIRA CGT, et al. Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort. Frontiers in Immunology, 2022; 13: 908398.
TORRES-FLORES JM, et al. Dengue Vaccines: An Update. BioDrugs, 2022; 36(3): 325–36.
TRICCO AC, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Annals of Internal Medicine, 2018; 169 (7): 467–473.
WHO. Disease Outbreak News: Dengue – Global situation. 2023. Disponível em: https ://www.who.int /emergencies/disease-outbreak-news/item/2023-DON498.
WILDER-SMITH A. Dengue vaccine development: status and future. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2020; 63(1): 40–4.